

This is a repository copy of *We need to talk about values:a proposed framework for the articulation of normative reasoning in health technology assessment*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/198649/>

Version: Published Version

---

**Article:**

Charlton, Victoria, DiStefano, Michael, Mitchell, Polly et al. (20 more authors) (2023) We need to talk about values:a proposed framework for the articulation of normative reasoning in health technology assessment. Health Economics, Policy and Law. pp. 1-21. ISSN: 1744-1331

<https://doi.org/10.1017/S1744133123000038>

---

**Reuse**

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>










**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



ARTICLE

# We need to talk about values: a proposed framework for the articulation of normative reasoning in health technology assessment

Victoria Charlton<sup>1</sup> , Michael DiStefano<sup>2,3</sup> , Polly Mitchell<sup>4</sup> , Liz Morrell<sup>5</sup> , Leah Rand<sup>6</sup> , Gabriele Badano<sup>7</sup> , Rachel Baker<sup>8</sup> , Michael Calnan<sup>9</sup> , Kalipso Chalkidou<sup>10</sup> , Anthony Culyer<sup>11</sup> , Daniel Howdon<sup>12</sup> , Dyfrig Hughes<sup>13</sup> , James Lomas<sup>11</sup> , Catherine Max<sup>14</sup>, Christopher McCabe<sup>15</sup> , James F. O'Mahony<sup>16</sup> , Mike Paulden<sup>17</sup> , Zack Pemberton-Whiteley<sup>18</sup>, Annette Rid<sup>19</sup> , Paul Scuffham<sup>20</sup> , Mark Sculpher<sup>11</sup> , Koonal Shah<sup>21</sup> , Albert Weale<sup>22</sup>  and Gry Wester<sup>23</sup> 

<sup>1</sup>Department of Global Health and Social Medicine, King's College London, London, UK, <sup>2</sup>Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, <sup>3</sup>Berman Institute of Bioethics, Johns Hopkins University, Baltimore, MD, USA, <sup>4</sup>School of Education, Communication and Society, King's College London, London, UK, <sup>5</sup>Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK, <sup>6</sup>Program on Regulation, Therapeutics and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Center for Bioethics, Harvard Medical School, Boston, MA, USA, <sup>7</sup>Department of Politics, University of York, York, UK, <sup>8</sup>Yunus Centre for Social Business and Health, Glasgow Caledonian University, Glasgow, Scotland, UK, <sup>9</sup>School of Social Policy, Sociology and Social Research, University of Kent, Canterbury, UK, <sup>10</sup>Centre for Global Development, London, UK, <sup>11</sup>Centre for Health Economics, University of York, York, UK, <sup>12</sup>Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK, <sup>13</sup>Centre for Health Economics and Medicines Evaluation, School of Medical and Health Sciences, Bangor University, Bangor, UK, <sup>14</sup>Catherine Max Consulting, London, UK, <sup>15</sup>Centre for Public Health and Queens Management School, Queens University Belfast, Belfast, UK, <sup>16</sup>Centre for Health Policy and Management, Trinity College Dublin, Dublin, Ireland, <sup>17</sup>School of Public Health, University of Alberta, Edmonton, Canada, <sup>18</sup>Leukaemia Care, Worcester, UK, <sup>19</sup>Department of Bioethics, The Clinical Center, National Institutes of Health, Bethesda, MD, USA, <sup>20</sup>Centre for Applied Health Economics, Menzies Health Institute Queensland, Griffith University, Gold Coast, Australia, <sup>21</sup>Science Policy and Research Programme, National Institute for Health and Care Excellence, London, UK, <sup>22</sup>School of Public Policy, University College London, London, UK and <sup>23</sup>VMLY&R Health, London, UK

**Corresponding author:** Victoria Charlton; Email: [Victoria.charlton@kcl.ac.uk](mailto:Victoria.charlton@kcl.ac.uk)

(Received 22 February 2022; revised 2 March 2023; accepted 4 March 2023)

## Abstract

It is acknowledged that health technology assessment (HTA) is an inherently value-based activity that makes use of normative reasoning alongside empirical evidence. But the language used to conceptualise and articulate HTA's normative aspects is demonstrably unnuanced, imprecise, and inconsistently employed, undermining transparency and preventing proper scrutiny of the rationales on which decisions are based. This paper – developed through a cross-disciplinary collaboration of 24 researchers with expertise in healthcare priority-setting – seeks to address this problem by offering a clear definition of key terms and distinguishing between the types of normative commitment invoked during HTA, thus providing a novel conceptual framework for the articulation of reasoning. Through application to a hypothetical case, it is illustrated how this framework can operate as a practical tool through which HTA practitioners and policymakers can enhance the transparency and coherence of their decision-making, while enabling others to hold them more easily to account. The framework is offered as a starting point for further discussion amongst those with a desire to enhance the legitimacy and fairness of HTA by facilitating practical public reasoning, in which decisions are made on behalf of the public, in public view, through a chain of reasoning that withstands ethical scrutiny.

© National Institutes of Health and the Author(s), 2023. To the extent this is a work of the US Government, it is not subject to copyright protection within the United States. Published by Cambridge University Press. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.

**Keywords:** healthcare priority-setting; ethics; social values; moral values; practical public reasoning

## 1. Background

Health technology assessment (HTA) is the systematic evaluation of the properties, effects, or impacts of health technology (Goodman, 1998; WHO, 2021).<sup>1</sup> It is used by both public and private organisations to inform decisions about the availability of interventions within the health system, with profound implications for the health and wellbeing of members of society.

HTA makes significant use of empirical evidence, but its evaluative aim is inherently normative – that is, value-based (Hofmann *et al.*, 2014, 2018; Legault *et al.*, 2021). The normative grounds for healthcare priority-setting are highly contested: there is little societal agreement about what constitutes a fair distribution of scarce healthcare resources. Healthcare priority-setters and those undertaking HTA for policy purposes thus face a significant challenge in seeking to make well-justified decisions that will be accepted by all as fair and legitimate in the face of disagreement about what is the right decision.<sup>2</sup> This challenge may be even greater when priority-setting decisions are made by private organisations that lack the political authority of public institutions.

To date, problems of legitimacy and fairness have been addressed largely through procedural means. Norman Daniels and James Sabin's well-known accountability for reasonableness framework, for example, is a widely adopted approach that rests heavily on the requirement that those employing HTA to inform healthcare priority-setting are transparent about their decisions and the reasoning behind them (Daniels and Sabin, 1997). However, defensible HTA decision-making also requires that the substantive rationales underpinning such decisions stand up to moral scrutiny and are clearly enough articulated to allow for reasoned debate between stakeholders who may disagree about the course of action (Culyer and Lomas, 2006; Daniels and Van der Wilt, 2016). An approach that incorporates practical public reasoning – in which decisions are made on behalf of the public, in public view, through a chain of reasoning that brings normative commitments together with empirical evidence in reaching a conclusion that can be morally justified on both procedural and substantive grounds – has the potential to not only improve decision-making, but also to strengthen fairness and the perceived legitimacy of the HTA body and its decisions (Weale, 2010; Rumbold *et al.*, 2017; Charlton and Weale, 2021).<sup>3</sup>

To date, the practice of practical public reasoning in healthcare priority-setting has been hindered by limitations in the language used to articulate normative aspects of HTA (Bellemare *et al.*, 2018; Charlton and Weale, 2021). This paper attempts to address this challenge.

<sup>1</sup>Other definitions of HTA exist, including one recently developed by O'Rourke *et al.* (2020), as the output of an international joint task group co-led by the International Network of Agencies for Health Technology Assessment and Health Technology Assessment International. However, we prefer to use the definition by Goodman for the reasons set out in Culyer and Husereau (2022) and because this definition, unlike O'Rourke, does not make any assumptions about the underlying normative aims of HTA.

<sup>2</sup>The question of how legitimacy is defined and derived is a dense one that goes well beyond the scope of this paper. We do, however, follow Buchanan in distinguishing between perceived (i.e. descriptive) legitimacy and normative legitimacy (Buchanan, 2002) and note that both forms can have multiple sources; for example, political or legal process, morality, public opinion, and so on. Our starting point for this paper is that, given the highly normative and contentious nature of healthcare priority-setting, a decision-maker's ability to provide moral justification for their actions is an especially important source of both perceived and normative legitimacy in this field.

<sup>3</sup>While this paper focuses on perceived or descriptive legitimacy, we note that different forms of perceived legitimacy can come apart. A well-reasoned and morally justified HTA process may be described as legitimate according to codified institutional, political, or legal processes, but not perceived to be legitimate or accepted by the general public. Empirical claims about public perceptions of legitimacy are beyond the scope of this paper. When we refer to 'perceived legitimacy' we mean the extent to which decision-making requirements set by or expected of HTA bodies are met; for example, that they provide defensible explanations for their judgements and recommendations. We do not address the further question of whether such requirements give decision-making processes normative legitimacy.

## 2. Normativity in HTA: an enigmatic sphere, ambiguously described

There have been many calls in the literature for increased attention to be given to the ethical dimensions of HTA (Hofmann, 2008; Saarni *et al.*, 2008; Schokkaert, 2015; Bellemare *et al.*, 2018; Legault *et al.*, 2021; Oortwijn and Sampietro-Colom, 2022). However, across academic literature and in the description and practice of applied HTA, normative aspects of decision-making are described using a variety of imprecise terms, which are employed inconsistently and lack the sensitivity to distinguish between different types of normative commitment. This gives rise to ambiguity about the rationale for individual priority-setting decisions. While such ambiguity may serve a useful function in helping decision-makers to respond pragmatically to ethically and politically challenging circumstances – that is, to ‘muddle through elegantly’ (Hunter, 1995; Mechanic, 1997; Calnan *et al.*, 2017) – it also potentially facilitates dubious practices such as the deliberate obfuscation of reasons that cannot be morally justified or the abandonment of principles in favour of political, professional, or personal interests. Intentional or not, ambiguity in the language used to describe normative aspects of HTA is therefore problematic.

One term frequently employed in this context is ‘social value judgement’, whose use was popularised through a 2005 document produced by the UK’s National Institute for Health and Care Excellence (NICE) – an acknowledged HTA innovator. ‘Social Value Judgements: Principles for the development of NICE guidance’ used the term to describe what NICE understood to be its normative commitments, defining it in explicitly moral terms as ‘an ethical opinion [...] that a particular course of action, institutional arrangement or method of analysis ought to be implemented, or is itself good’ (NICE, 2005). NICE’s definition of ‘social value judgement’ has since undergone several iterations.<sup>4</sup> At present, it grounds the term firmly on social rather than moral norms, describing a social value judgement as a judgement that ‘take[s] account of society’s expectations, preferences, culture and ethical principles’ (NICE, 2021). It is unclear what this definition implies about the relationship between social and moral values, however, or how this notion should be applied to ethical questions on which societal consensus is lacking.<sup>5</sup> It is also unclear how NICE distinguishes between a social value judgement and a principle – an alternative term that has recently become more prominent in NICE documentation (NICE, 2020).

A lack of consistency and clarity in adopted language is also evident within and across other HTA bodies. Australia’s Pharmaceutical Benefits Advisory Committee (PBAC) distinguishes between ‘quantifiable’ and ‘less-readily quantifiable’ considerations in HTA, including in the latter category specific normative issues such as ‘implicit equity and ethical assumptions such as age, or socioeconomic and geographical status’ (PBAC, 2016). France’s Haute Autorité de Santé (HAS) refers to such issues as part of its ‘assessment of ethical aspects’, which it defines as those matters that ‘involve the values that concern the conditions of living together’ – that is, ‘social values’ (HAS, 2014). The Canadian Agency for Drugs and Technologies in Health (CADTH) also conducts an ‘ethics review’ for certain complex technologies, intended to describe the ‘ethical issues relevant to the drug’s target population(s), evidentiary basis, use, implementation and outcomes’ (CADTH, 2023).

The Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) groups together ‘ethical and social aspects’ related to a technology’s application (SBU, 2018), while the US Institute for Clinical and Economic Review (ICER) additionally includes legal issues within this category of ‘contextual considerations’ (ICER, 2020). In contrast, the HTA Core model – a methodological framework developed by a network of European HTA agencies – treats ‘ethical analysis’, ‘patient and social’, and ‘legal’ as separate domains, while acknowledging the relevance of ‘value judgements’ to all domains of HTA (EUnetHTA, 2016). Given the variation in language across just

<sup>4</sup>For example, as judgements that ‘relate to society rather than science’ (NICE, 2008), as judgements that concern ‘what is good for society’ (Rawlins and Culyer, 2004), or as judgements about ‘what is appropriate and acceptable for society’ (Rawlins *et al.*, 2010).

<sup>5</sup>This is not an uncommon issue in HTA (Otto *et al.*, 2021).

these few examples, common understandings are difficult to identify, and it is perhaps unsurprising that HTAGlossary.net (2021) includes none of these terms within its 300+ entries.

Similar issues are also present in the academic literature. In a 2012 journal issue focused on ‘social values’ in health priority-setting, one paper describes these as ‘the values of the public or society, including their moral values’, suggesting that the latter is a subset of the former (Biron *et al.*, 2012), while another describes them solely as ‘the moral or ethical values of a particular society’ (Clark and Weale, 2012). Stafinski *et al.* (2011) typify the health economic literature in defining social values in non-moral terms as the ‘distributive preferences of the public for healthcare among populations’. Unusually, Orr *et al.* (2011) distinguish between the preferences of individuals and the ‘citizen perspective’, defining social values as ‘values that the public generally feel are important for society at large, often regardless of one’s own preferences’. More unusually still, Nicod and Kanavos (2016) define them as ‘non-elicited preferences’ that, in the context of HTA, ‘originate from the individual appraisal committee member’s value judgment based on their experience or on what they believe society would prefer’. According to a recent systematic review, many authors avoid definitional problems by simply not specifying the nature of the normative concepts that they describe, in particular ‘whether they consist of social values, moral norms, or value judgments’ (Bellemare *et al.*, 2018).

The aim of this paper is to address such difficulties directly by defining key terms and presenting a tool that allows reasoning in HTA to be more clearly and precisely articulated. Our hope is that this will be of practical use to HTA practitioners and policymakers, while also supporting the work of those who seek to hold healthcare priority-setters to account. In addition, we hope that the paper will stimulate more constructive discussion in the academic literature by reducing confusion across disciplinary boundaries.

### 3. Methods

This paper represents the output of a collaboration involving 24 co-authors, all of whom have significant knowledge and expertise in the policy, ethics, and/or economics of healthcare priority-setting. The framework<sup>6</sup> that it describes was developed through a group method in which the problem identified above was characterised through several rounds of discussion, before an approach to addressing it emerged through further cycles of idea generation, discussion, and refinement (Steyaert and Bouwen, 2004). The preparation of the current paper was led by a small writing group<sup>7</sup> with all other co-authors contributing to the critical revision of an initial draft. The proposed framework is offered as a starting point for further debate and development and it is hoped that engagement with others working in this field will contribute to its legitimacy as a practical tool to support priority-setting.

We proceed by providing a brief overview of the proposed framework, before introducing each of its key concepts and illustrating its utility through application to a simplified hypothetical case. We then discuss the framework’s advantages in terms of its ability to facilitate transparency across the chain of reasoning and increase moral scrutiny of decision-making. The paper concludes by considering how the framework might be used to improve the legitimacy and fairness of HTA as a tool for public policy.

## 4. Results

### 4.1 Overview: a tool for articulating normative reasoning in HTA

The framework rests on the view that HTA is an activity which is shaped by a range of evaluative considerations, claims, and beliefs. It terms these **normative commitments**. Normative


<sup>6</sup>Following Dawson (2009), we understand a framework to be a practically oriented tool, specific to a particular problem or activity, which aids deliberation by making values explicit. Our framework is specific to the activity of HTA, and its intention is to aid both the quality and transparency of the reasoning on which HTA-informed decisions are based.

<sup>7</sup>The writing group comprised VC, MD, PM, LM, and LR.

commitments differ from one another both in their content (i.e. in their conception of how the world ought to be) and in their degree of specification (i.e. the extent to which they guide specific action). We have argued in the previous section that current limitations of language regularly obscure the chain of reasoning that links such commitments in justifying decisions informed by HTA.

The framework addresses this limitation by distinguishing between **values, principles, standards, and case-based judgements**: four relatively distinct types of normative commitment that range from the highly abstract (values) to the context specific (case-based judgements) (Figure 1; Table 1). The lines between these categories are not absolute. But, in general, values will be set at the organisational level and may also reflect beliefs held across the health system (or even society) as a whole. Principles will usually be organisational, standards will typically relate specifically to a programme of technology assessment, and case-based judgements will be made in response to the consideration of an individual technology and/or indication. Use of this framework therefore facilitates a structured articulation of the chain of reasoning that underlies decision-making – from more abstract and indeterminate values down to highly specified case-based judgements – and clarifies the role that empirical evidence has played in this chain.

The practical utility of this approach will be illustrated through the framework's application to a hypothetical case, introduced below. It is important to note that this case is, by design, simplified and is not intended to reflect the approach of any particular HTA body. As will become evident, it is also not constructed to illustrate a morally justified decision. Rather, it aims to demonstrate how the framework can make normative aspects of HTA more transparent, such that the rationale for decisions is made more open to reasoned debate and scrutiny.



**Figure 1.** Overview of the framework.



Table 1. Definitions

<i>Underpinning terms</i>	
Normative	Relating to an evaluation of how the world ought to be.
Empirical	Relating to a description of how the world is, or a prediction of how the world will be.
Substantive	Relating to what decisions are made and why.
Procedural	Relating to how decisions are made.
Morally based	Derived from moral theory. May or may not reflect beliefs commonly held by society and cannot be derived solely from empirical investigation of such beliefs.
Socially based	Derived from societal preferences. May or may not be justifiable with reference to moral theory and cannot be derived solely from such theory. Can be derived solely from empirical investigation.
<i>Components of the framework</i>	
Normative commitment	An evaluative consideration, claim or belief. Classified by the framework into four types: values, principles, standards and case-based judgements.
Value	An abstract end that is worth pursuing because it is ‘good’ or ‘right’.
Principle	A general statement that serves as a pledge to act in a certain way, as a guide for behaviour, or as the basis for part of a chain of reasoning. Principles broadly capture the conditions under which an action might be regarded as right or wrong.
Standard	Ways of doing things that are accepted by authority, precedent, custom or general consent.
Formal standard	A standard that is codified in policy.
Informal standard	A standard that has been established through individual cases and is not codified in policy. May become formalised over time.
Case-based judgement	A considered conclusion reached through the evaluation of information relevant to a specific context or case, in light of relevant values, principles and standards.
Evidential judgement	A case-based judgement about what one ought to believe about the world, given the available information.
Ethical judgement	A case-based judgement about how one ought to act.
Recommendation	A proposal or resolution to pursue a particular course of action. In the context of HTA, this usually relates to whether a particular health technology should be adopted and on what terms.

4.2 The hypothetical case: *Gehrigole*<sup>8</sup> for the treatment of amyotrophic lateral sclerosis

*Gehrigole is a new drug treatment for amyotrophic lateral sclerosis (ALS), one of several disorders in which degeneration of motor neuron cells in the brain and nervous system leads to muscle weakness. ALS generally affects people aged 50–65 and typically leads to substantially reduced quality of life and death within 3–5 years of diagnosis, often due to respiratory failure. Gehrigole’s manufacturer claims that its new drug counteracts ALS by acting on a molecular pathway that has not previously been the target of pharmacological treatment. As a result, the national healthcare regulator has formally designated Gehrigole an ‘innovative medicine’.*

*In a large head-to-head randomised controlled trial (RCT) conducted in South-East Asia over 3 years, Gehrigole appeared to show some benefits compared to standard treatment. When initiated immediately following diagnosis, patients receiving Gehrigole reported a clinically meaningful improvement in symptoms and their requirement for assisted ventilation was delayed by an average of 53 days compared with the control group. Average length of post-diagnosis survival was also 20*

<sup>8</sup>Derived from Lou Gehrig, the American baseball player whose career was famously curtailed by the disease in the 1930s (Augustyn, 2020).

days longer than in the control group, although this relationship did not reach statistical significance. Based on application of a standardised quality of life questionnaire, these benefits were associated with a utility gain of approximately 0.15 quality-adjusted life-years (QALYs) compared with existing treatment.

In assessing this evidence, the national regulator expressed some concern about approving a novel medicine based on a single, relatively short trial and noted that there was uncertainty about how generalisable the findings would be to its own population. However, as a result of Gehrigole's 'innovative medicine' designation, the regulator judged that it was appropriate to tolerate a relatively high level of uncertainty and deemed this sufficient evidence to grant marketing authorisation.

Priority-setter A has authority to make recommendations on behalf of the national health system. It delegates its decision-making about individual cases to an independent committee made up of clinicians, health economists, and patient representatives. This committee is using HTA to inform its view on whether Gehrigole should be adopted.

### 4.3 Values

Values are the most abstract of the framework's four types of normative commitment.

Value is generally understood to be a claim about something's worth. However, philosophers and economists tend to differ in their application of the concept to HTA. For economists, value is usually an empirical claim about the extent to which certain states or things are observed (or believed) to be preferred over others. This notion of value plays an important role in HTA, primarily as a source of empirical evidence about a technology's anticipated effects, in terms of either comparative clinical effectiveness or cost-effectiveness.<sup>9</sup> This economic conception of value is, however, distinct from the philosophical understanding of a value as an abstract end that is worth pursuing because it is 'good' or 'right': ends such as justice, liberty, dignity, and happiness. It is this latter conception of value that the framework describes as a form of normative commitment.

Within this philosophical conception, a distinction can be drawn between socially and morally based values. In a society in which there is a strong sense of 'common morality', these may be closely aligned. However, social and moral values can also diverge. Society may hold dubious values which, though popular, cannot be morally justified. Similarly, individuals may hold self-interested preferences that differ from what they believe is 'right'.<sup>10</sup> Preference-derived social values may also not reflect the views of 'society' in any simple sense; rather, they may represent the views of the majority, or of special interests, or of a group charged with expressing such views on behalf of society, rather than reflecting the plurality of views present across society as a whole (Baker *et al.*, 2021; Charlton and Weale, 2021).

*In its formal charter, priority-setter A promises that it will act in accordance with three values: justice, liberty, and integrity. It does not commit to any single moral theory but considers these values to be morally based because they reflect its desire to act for the good of society. It also considers them to be socially based in so far as they are thought to reflect society's views about how public bodies ought to act. The influence of these values is also evident in the legislation through which priority-setter A was established and in which its statutory role is defined: to 'provide unbiased recommendations on the fair distribution of healthcare resources across the population'. Priority-setter A pledges to be guided by these values in its consideration of Gehrigole, as in all its actions.*

<sup>9</sup>Use of standardised instruments such as the EQ-5D, for example, allows value to be assigned to various health states based on population preferences (Dolan, 1997).

<sup>10</sup>For example, a person might eat meat because of its nutritional value, or because they enjoy the taste, despite believing that the commercial husbandry of animals is morally wrong.



#### 4.4 Principles

All attempts to set healthcare priorities rest on values, whether or not they are explicitly acknowledged. However, values are, by their nature, insufficiently specified to determine the choice of one course of action over another. One way of specifying how particular values are to be understood and interpreted is through the stipulation of **principles**. Principles broadly capture the conditions under which an action might be regarded as right or wrong and therefore serve as a pledge to act in a certain way, as a guide for behaviour, or as the basis for part of a chain of reasoning.

Principles can be categorised as either **substantive** or **procedural**. Substantive principles relate to what decisions are made and why, specifying features that ought to be manifested in the decision outcome. Procedural principles relate to how decisions are made, specifying features that ought to be present in the decision-making process. The claim that health systems should generate as much population health as possible – a principle of health maximisation – is a substantive principle that represents one possible specification of the value of justice. However, the value of justice might also be specified through a procedural principle of consistency, according to which priority-setting decisions should be reached through the application of a consistent set of procedures. In some cases, different specifications of a given value may give rise to principles that are in tension with one another, as may principles derived from different values. Such tensions can be resolved either through further specification of general rules of action (i.e. through **standards**) or on a case-by-case basis (i.e. through **case-based judgements**).

*Priority-setter A specifies its commitment to the value of justice through three substantive principles. First, it states that cases that are alike in morally relevant respects should be treated similarly. It refers to this as its principle of equality. Second, it proposes that everyone should have the ability to live life in a reasonable state of health, and that priority should therefore be given to addressing the clinical needs of those in poor health. It refers to this as its principle of clinical need. Third, it considers that the health service (which operates under a fixed budget) exists to serve everyone and that, all else being equal, adoption of a technology that displaces more health than it generates is unjust. It refers to this as its principle of efficiency. Priority-setter A acknowledges that these principles may sometimes be in tension with one another and that there is no moral or societal consensus about how they should be balanced. It also acknowledges that uncertainty in the available evidence may sometimes make it difficult to reach reliable conclusions about how the use of any given technology might impact on the realisation of these principles.*

*In seeking to act justly and with integrity, priority-setter A has also specified several procedural principles. These include principles of consistency, transparency, inclusiveness, independence, and consensus-based decision-making. It has also pledged to act in accordance with the value of liberty, which it believes is directly served by respecting the rule of law. This last principle takes precedence over all other substantive and procedural principles.*<sup>11</sup>

#### 4.5 Standards

At a further level of specification lie **standards**: ways of doing things that are accepted by authority, precedent, custom, or general consent. Like principles, standards can be either substantive or procedural.

In their operationalisation of values and principles, standards act as a bridge between relatively abstract normative commitments and the specific judgements that must be made in response to individual cases. **Formal standards** are standards that have been codified in policy. For example, the so-called ‘reference case’ in HTA tends to comprise multiple formal substantive standards that

<sup>11</sup>Respect for the rule of law potentially constrains a priority-setter’s specification of several substantive and procedural principles; for example, legal data protection requirements may limit the transparency of certain aspects of decision-making, while equalities laws may impact a priority-setter’s ability to differentiate between certain groups.

govern how a technology's potential impacts should be measured and evaluated,<sup>12</sup> while other policies may stipulate when exceptions to the reference case might be considered acceptable. Formal procedural standards may describe different features of the overall decision-making process, such as how participants in appraisal processes will be selected, how the process will be facilitated, and whether meetings will be open to the public (Oortwijn *et al.*, 2022). Unlike formal standards, **informal standards** are established through precedent and are not codified in policy. While formal standards are likely to be applied consistently – because departure from them will be visible and can be easily challenged – informal standards are less obvious to external stakeholders and may be applied inconsistently. Over time, informal standards may become entrenched and eventually formalised.<sup>13</sup>

Standards offer a way of specifying normative commitments, but they may also be heavily informed by empirical evidence, including economic conceptions of value. For example, an insurer might use evidence on the public's willingness to pay for a particular drug to inform standards concerning who is given access to that drug and under what terms. Indeed, the technical nature of some standards may conceal their normativity from all but those with relevant expertise. Standards concerning discount rates, for instance – that is, the rate at which future health gains should be discounted compared with health gains experienced immediately – are highly technical in their use of empirical evidence (Attema *et al.*, 2018), but also rest on normative choices (O'Mahony and Paulden, 2014). The normative nature of such technically complex standards often goes unacknowledged and is rarely discussed during the 'ethical analysis' phase of an HTA process or as part of HTA bodies' reflection on their 'social value judgements'.

One type of formal standard frequently adopted by HTA bodies is a cost-effectiveness threshold. Different conceptions of this standard are discussed in Box 1. HTA bodies that do not rely on cost-effectiveness analysis may instead base their decisions on formal standards used to determine the added clinical benefit of particular technologies, which then informs pricing decisions.

*Priority-setter A has specified its substantive principle of efficiency by embedding several formal standards within its reference case. These include use of cost-utility analysis, measurement of health gains in QALYs, and the exclusion of non-health and indirect effects. The use of a reference case also partially operationalises its procedural principle of consistency. In addition, priority-setter A has established a formal standard which requires it generally to reject technologies whose cost exceeds \$50,000/QALY. Although direct evidence for the opportunity cost associated with the adoption of new technologies is not available for this health system, this 'cost-effectiveness threshold' has been established through precedent and is considered by priority-setter A to be the point at which a new technology's adoption is likely to displace more health than it generates. It is therefore an attempt to operationalise its principle of efficiency, as well as its principle of equality and its conception of the value of justice, by ensuring that known and unknown beneficiaries of the health system are treated equally, absent a specific reason to do otherwise.*

*One such reason is disease severity, arising from its principle of clinical need. The relative weight of this principle compared with other substantive principles is not specified by any formal standard. However, priority-setter A has shown itself willing in several previous cases to recommend technologies whose costs exceed \$50,000/QALY if clinical need is judged to be substantial and the estimated resource impact is small. It has also shown itself willing to tolerate greater uncertainty if the potential health benefits are large, although this is also not formally acknowledged or justified. These*

<sup>12</sup>According to one definition, 'the reference case gives a formal statement of accepted methods and assumptions underpinning analyses to which submissions should conform' (YHEC, 2016). Standards typically specified as part of the reference case include choice of comparator, perspective taken in calculating costs and benefits, time horizon, discount rate, sources of data, and preferred type of economic evaluation.

<sup>13</sup>This transformation from informal to formal standard has occurred on multiple occasions at NICE, for example, in the establishment of both its usual cost-effectiveness threshold and its increased threshold for use in assessing certain end-of-life technologies (Charlton, 2020).

**Box 1.** Conceptions of cost-effectiveness

The measure often used in HTA to determine whether an intervention should be considered cost-effective is conceptualised in two main ways, with differences often obscured in the common notion of the ‘cost-effectiveness threshold’ (McCabe *et al.*, 2008; Culyer, 2016; Thokala *et al.*, 2018). The framework provides a means to more precisely and accurately articulate the normative distinctions between these different conceptions of cost-effectiveness.

**1. Cost-effectiveness based on opportunity cost.** This ‘supply side’ notion of cost-effectiveness is concerned with the health service’s ability to generate health from marginal changes in expenditure. It is applicable in any system in which there are limits to healthcare expenditure. Introducing a new technology necessarily means that the funds required for its adoption cannot be put to other uses, resulting in foregone health from some other part of the health system. The threshold represents the cost per unit of health gain above which the forgone health exceeds the health gained from the new technology, leading to an overall loss of population health. According to the framework’s terminology, this type of threshold acts as either a **formal or informal standard** that is derived from a **substantive principle** of efficiency. This **morally based** principle specifies the underlying **value** of justice, such that the most just distribution of health resources is understood to be that which leads to the greatest net gain in population health.

**2. Cost-effectiveness based on willingness to pay.** This ‘demand side’ notion of cost-effectiveness is concerned with the value placed on healthcare by the population; that is, how much individuals or societies are prepared to pay for a unit of health gain. This type of threshold can be described by the framework as a **formal or informal standard** that is **socially based** and reflects a **substantive principle** of aggregated societal preference and a **procedural principle** of inclusiveness. Together, these principles imply that members of society should be able to prioritise access to healthcare based on their own inclinations and that all such inclinations should be incorporated in an aggregated estimate of the cost-effectiveness threshold. Both principles can be derived from the **value** of liberty (or similar).

These two conceptualisations are intimately linked. The demand-side concept reflects how much a society is prepared to spend on health, hence in principle informing the budget for healthcare. This budget directly determines the supply side threshold. (For a full explanation see McCabe *et al.*, 2008; Culyer, 2016; Paulden *et al.*, 2017.)

Although there are empirical methods to estimate either of these types of threshold, many thresholds in current use have been identified by anchoring to reference points such as previous decisions, specific interventions assumed to be necessary or cost-effective, or a country’s GDP per capita. Such approaches need not be considered as alternative conceptualisations of a threshold, but rather as pragmatic approaches to identifying it. The terminology offered by the framework enables the various normative commitments that underlie each of these approaches to be more clearly articulated.

1. NICE (2021).

2. Bullement *et al.* (2019).

*constitute informal standards that are relatively unspecified and may be interpreted differently in different cases, potentially undermining priority-setter A’s substantive principle of equality and its procedural principle of consistency.*

*In addition to these substantive standards, several procedural standards are in place to detail how such decisions should be reached in a way that accords with its principles of inclusiveness, independence, and consensus-based decision-making.*

*In consideration of these standards, the manufacturer of Gehrigole has presented its evidence as a cost-utility analysis. This analysis includes evidence relating to patients’ functional abilities, survival, and quality of life but excludes evidence about indirect and non-health effects such as the impact on family members and on patient employment and earnings. The manufacturer is aware of priority-setter A’s informal standard relating to clinical need and has drawn attention to the severity of ALS, the relatively large health benefits potentially offered by Gehrigole and its relatively small resource impact. The manufacturer has highlighted in its communications with priority-setter A that it considers this evidence to be robust and its view that Gehrigole is highly likely to deliver the clinical benefits presented in its analysis.*

#### 4.6 Case-based judgements

The most specified type of normative commitment is **case-based judgements**: considered conclusions reached through the evaluation of information relevant to a specific context or case. The framework classifies case-based judgements into two forms: evidential and ethical.

**Evidential judgements** are case-based judgements about what one ought to believe about the world, given the information that is available. In the context of HTA, these relate primarily to the anticipated outcomes of a technology's adoption and the credence given to different sources of evidence on these outcomes.

Evidential judgements draw substantially on empirical data, which may require a high level of technical competence for their proper interpretation and application to decision-making. However, evidential judgements also incorporate normative commitments which can be taken to ground knowledge claims; these include widely accepted epistemic standards, such as the definition of statistical significance, and norms for the conduct and reporting of clinical trials. Other evidential judgements relate to how individuals and priority-setting committees interpret and attribute weight to the data that is presented to them. These might include judgements about how much credibility should be ascribed to evidence produced by different parties and about how uncertainty should affect the conclusions reached. As in the case of standards, the highly technical nature of such judgements may conceal the extent to which they are based on normative commitments as well as empirical data.

Some evidential judgements can be codified as standards. However, it will always be necessary to consider the features of the individual case in deciding how to apply these standards. For instance, a priority-setter might specify as a standard that evidence generated by RCTs should be considered more reliable than 'real-world' observational data, but the weight given to evidence produced by a particular RCT will depend on judgements made about the strengths and limitations of that particular trial. Individual cases will also sometimes generate novel case-based judgements. For instance, decision-makers might occasionally be faced with new types of technology or new ways of collecting evidence, to which existing standards are not applicable, or, in the absence of clearly defined standards, may find themselves making case-based judgements about how uncertainty should affect the conclusions reached. Over time, formalisation of such judgements as standards is likely to improve the consistency and transparency of decision-making.

*The manufacturer's submission indicates that Gehrigole comes at an incremental cost of \$45,000/QALY compared to standard of care. Priority-setter A has not specified in its formal standards its attitude to risk or how it responds to uncertainty in the available evidence. In evaluating this estimate of cost-effectiveness, it therefore relies on informal standards and several case-based evidential judgements. First, it notes that its evidence for decision-making is derived from a single trial conducted in South-East Asia. It judges that the results of this trial may not be generalisable to its own health system due to differences in standard of care and patient demographics. Second, it notes that though the trial was randomised and controlled – and that RCTs are usually considered to be a reliable source of evidence – it was of relatively short duration and the manufacturer's approach to extrapolating survival data is the most generous of several possible scenarios. It judges that, given the failure of the observed effect to reach statistical significance even using this approach, any apparent survival benefit should be considered highly uncertain. Third, it observes that the manufacturer has a significant commercial interest in securing adoption of its drug and is therefore incentivised to take a favourable view of the likely magnitude of clinical benefits and the robustness of the available evidence. It therefore judges – as it has in previous cases – that the manufacturer's model is highly likely to overestimate the drug's clinical effectiveness and that Gehrigole is likely to have been priced based on the maximum cost thought likely by the manufacturer to be deemed acceptable by the committee.*

*Taking these evidential judgements together, priority-setter A concludes that Gehrigole is unlikely to offer any significant survival benefit and that the drug's cost probably exceeds*

\$50,000/QALY. However, it accepts that Gehrigole does likely offer some benefits in terms of quality of life – albeit less than the 0.15 QALYs suggested by the available evidence – and that its novel mechanism of action represents a significant scientific advance. It agrees with the manufacturer’s assessment that the financial impact of Gehrigole’s adoption on the health system would amount to around \$15 million per year.

Operating alongside evidential judgements are case-based **ethical judgements** about how one ought to act. In the context of HTA these relate primarily to whether a particular technology should be adopted for use and on what grounds.

The ethical judgements made during HTA are informed by empirical information and the evidential judgements that arise from it. However, while empirical evidence is required to establish the likely effects of a technology’s adoption and may additionally indicate how some people would trade these off against each other, such data do not in themselves determine what should be done. Rather, in deciding whether to adopt a technology, a decision-maker will be required to make a series of ethical judgements. As demonstrated below, in attempting to balance such judgements, priority-setters may occasionally find themselves reaching conclusions that are not morally coherent.

As in the case of evidential judgements, the consistency and transparency of decision-making is likely to be improved over time by codifying certain case-based ethical judgements as standards. However, attention will always need to be given to the specific features of the individual case in deciding how these standards should be applied and the need to make case-based ethical judgements will likely continue to arise, even in a highly formalised process.

*After weighing the evidence concerning Gehrigole’s likely effects, priority-setter A makes several case-based ethical judgements. Underpinning each of these is the evidential judgement that Gehrigole’s cost exceeds \$50,000/QALY and that its adoption would therefore likely lead to a net loss of QALYs from the population.*

*First, priority-setter A considers how to weigh its concern for efficiency against its principle of clinical need. It notes the severity of ALS – specifically, the short-life expectancy and poor quality of life experienced by patients at an advanced stage of the disease – and acknowledges that members of this group are in extremely poor health and therefore warrant prioritisation. Historically, it has traded efficiency off against clinical need in such cases by showing a willingness to exceed the usual cost-effectiveness threshold (an informal standard). It is aware that this approach is potentially incoherent in that it fails to give equivalent weight to the needs of those within the general population who are in a comparable state of poor health. Nevertheless, it makes an ethical judgement that to deviate from an established (if informal) standard would be to contravene the principle of formal equality, which requires it to treat identifiable cases that are alike in morally relevant respects similarly. It therefore decides to accept an incremental cost-effectiveness ratio somewhat greater than \$50,000/QALY for Gehrigole.*

*Second, it considers patient population size. Following extensive discussion and reflection on its normative commitments, priority-setter A can find no reason why ALS’s relative rarity compared with other conditions should justify deviation from its adopted principles. However, it notes that in previous cases it has been willing to accept a somewhat higher cost per QALY for rare conditions because of their relatively small impact on resources. Therefore, as in relation to severity, it makes an ethical judgement that its principle of equality requires it to maintain this established informal standard, despite its potential lack of moral justification. It therefore further uplifts its view of what constitutes an acceptable cost per QALY for Gehrigole.*

*Third, priority-setter A gives attention to Gehrigole’s pharmacological innovativeness, recalling its previous evidential judgement that the drug represents a significant scientific advance. It situates the normative value of this innovativeness in Gehrigole’s potential to contribute to an eventual cure for ALS, though it acknowledges that such an outcome is highly uncertain and that no further data can be gathered concerning its likelihood. It also notes its formal standard of excluding such indirect effects from consideration. However, given the significant unmet clinical need associated with*



ALS, it makes the ethical judgement that an exception should be made in this case and that these highly uncertain indirect benefits should be included in its assessment of Gehrigole. It therefore makes a further evidential judgement that whatever cost per QALY is derived from the available evidence, this is likely to undervalue Gehrigole's worth to society.

Finally, priority-setter A considers the age profile of the ALS patient population, noting that individuals in late middle-age often have children and older family members for whom they care (and who care for them). It is satisfied that this fact does not give rise to any direct health benefits that have not already been accounted for, but it considers whether there is a moral case for exceptionally including other indirect benefits of Gehrigole given the substantial impact of ALS on dependents' non-health-related quality of life. It makes the ethical judgement that to do so would be to prioritise treatment of these patients based on their age and social role and that, while it could be argued that these are morally relevant considerations, this would constitute illegal discrimination and would contravene the rule of law. It therefore does not take this factor into account in its decision-making.

#### 4.7 Recommendation

A single case will give rise to multiple judgements that might be used to justify a range of actions. The role of the decision-maker is to draw on these in reaching a resolution or proposal either to adopt or to reject the technology in question: a **recommendation**.

Some case-based judgements are likely to be repeated across cases, reflecting quite straightforwardly the values, principles, and standards of the priority-setter, and giving rise to a relatively uniform set of recommendations. But the idiosyncrasies of individual cases, the interpersonal dynamics of particular groups, and the discretion granted to decision-makers in deciding how to apply and balance different normative commitments mean that recommendations can rarely be predetermined: two committees may reasonably use the same information to reach different conclusions on different days. It is therefore only by articulating the full chain of reasoning that complete transparency about the rationale for a recommendation can be achieved.

Priority-setter A concludes that though Gehrigole likely does not meet the usual criteria for adoption, in this case its recommendation is justified by the severity and rarity of ALS and the drug's innovative nature. Priority-setter A therefore recommends that the health system adopt Gehrigole for the treatment of ALS.

### 5. Discussion

The preceding paragraph, in which priority-setter A gives the key reasons for its recommendation, is reflective of the type of abridged summary typically provided in HTA reports.<sup>14</sup> However, this offers a far from complete account of the normative conclusions reached in relation to Gehrigole or the role played by evidence in its evaluation. It is also the case that a full rationale for the approach taken to HTA is often absent at the level of policy; while some HTA bodies offer an account of the 'values', 'principles', 'morals', or 'ethics' that guide their approach to decision-making, it is often unclear how these have been derived, how they relate to one another, or how they are reflected in the more specified standards and judgements adopted in individual cases.<sup>15</sup>

<sup>14</sup>For example, the final paragraph of the 'Committee Discussion' section of NICE's technology appraisal guidance often resembles this type of abridged summary. Similar summaries of normative reasoning can also be found in the 'Committee Summary' issued by HAS, CADTH's 'Recommendation and Reasons', and PBAC's 'Public Summary Document'. For comparative examples relating to a single drug (Spinraza for the treatment of spinal muscular atrophy), see CADTH (2019); NICE (2019); HAS (2020); PBAC (2020).

<sup>15</sup>NICE's current 'Principles for the development of NICE guidance', for example, describes itself as explaining 'the morals, ethics and values that underpin our recommendations' but does not set out the normative basis for all of the principles that it lists and omits reference to several formal standards that play a central role in decision-making and which are potentially in tension with the general normative approach described (Charlton, 2021; NICE, 2021).



In contrast, the more detailed narrative facilitated by the framework illustrates the full chain of reasoning that underlies priority-setter A's recommendation of Gehrigole, opening this decision up to scrutiny and debate.

In this section, we highlight four specific ways in which use of the framework can enhance the legitimacy and fairness of decisions guided by HTA, by increasing transparency across the chain of reasoning and by ensuring that decisions can be defended as morally justifiable.

### 5.1 By making explicit the normative considerations that influence decision-making

In the case of Gehrigole, the concluding paragraph explicitly links priority-setter A's recommendation to three normative considerations: disease severity, rarity, and innovation. However, the full narrative facilitated through use of the framework makes clear that several other factors are implicated in the chain of reasoning. The most obvious is cost-effectiveness, which though alluded to is not explicitly acknowledged in the recommendation, potentially obscuring (at least to the non-expert) its central role in decision-making and the fact that the committee believes that the drug will displace more QALYs from the health system than it will deliver.<sup>16</sup> Also unacknowledged is the consideration given to patient age and social role, which contribute to the reasoning underlying priority-setter A's response to Gehrigole, despite ultimately being excluded. This significantly abridged account of priority-setter A's reasons also prevents external stakeholders from identifying any factors that may have been unintentionally overlooked or excluded on unclear grounds. Normative considerations underpinning priority-setter A's evidential judgements are similarly absent from this brief summary, such as its view that the manufacturer's commercial interests are likely to have influenced its estimate of Gehrigole's cost-effectiveness.

While reference to some of these factors may be included within the more detailed report that tends to accompany priority-setting decisions, their dispersal across lengthy and often highly technical documents significantly curtails their accessibility (Charlton, 2021). Moreover, limitations in the language currently adopted to describe such considerations hinder the articulation of a chain of reasoning that can be comprehended by those both involved in, and external to, the decision-making process. The framework offers a means of much more clearly and explicitly setting out such reasoning.

### 5.2 By specifying how normative considerations are understood and applied

Divorced from the chain of reasoning from which they are derived, reference to the normative importance attributed to factors such as disease severity, rarity, and innovation can give rise to ambiguity about the precise role that such factors play in decision-making and whether their treatment can be morally justified.

Taking disease severity as an example, HTA bodies frequently cite this factor in justifying a technology's adoption (Golan *et al.*, 2011; Angelis *et al.*, 2018; Kaur *et al.*, 2019). But they typically do not stipulate how severity is understood and do not acknowledge the values and principles that motivate its consideration. In contrast, the structured narrative facilitated by the framework specifies priority-setter A's understanding of severity and explicitly justifies the ethical judgement that stems from it: the view that the clinical needs of ALS patients should be prioritised due to their 'short life expectancy and poor quality of life'.

This type of articulation can also reveal the widely differing normative commitments on which identical recommendations can be based.

<sup>16</sup>The role played by cost-effectiveness in the chain of reasoning may be especially obscure in the context of price negotiation, which, though not a feature of our hypothetical case, often occurs in parallel with HTA and can lead to shifting ethical judgements about what constitutes an acceptable cost per QALY going unacknowledged or being misrepresented as evidential judgements.

Let us consider another organisation, priority-setter B. While priority-setter A's approach centres on the value of justice, understood primarily in terms of health outcomes, priority-setter B's approach rests on the values of human dignity and social solidarity. Drawing on these values, priority-setter B considers that the most severe diseases are those that most seriously diminish human dignity and that, in such cases, solidarity requires that society does what it can to reverse this harm. On this understanding, it judges ALS to be a very severe disease not because of its direct impact on QALYs, but because of its symptomology and the extent to which this undermines dignity; for example, by limiting patients' ability to walk, talk, eat, and breathe without assistance. Priority-setter B is therefore willing to suffer very significant opportunity cost to gain access to the relatively limited clinical benefits that Gehrigole seems to offer.

While both priority-setters A and B choose to recommend Gehrigole's adoption on the grounds of severity, the framework reveals that these decisions are based on very different normative commitments. It thereby opens such commitments up to reasoned debate amongst stakeholders, ensuring that justifications are offered for decisions grounded in normative commitments, and providing an opportunity for judgements that cannot be morally justified to be scrutinised and corrected.

### 5.3 By clarifying the relationship between empirical data and normative judgements

HTA draws on a variety of normative commitments which both shape and are shaped by empirical evidence and the application of technical expertise to its interpretation. However, when the evaluative conclusions of HTA become divorced from the reasoning that supports them, the distinction between the empirical and the normative – and the contribution of each to decision-making – often becomes blurred. Use of the framework is intended to clarify how evidence has been interpreted and evaluated during HTA and the role that it has played in decision-making. It also provides a structure for more clearly communicating uncertainty in HTA outputs (the importance of which has been highlighted elsewhere (Trowman *et al.*, 2021)) and through which inconsistencies in a priority-setter's attitude to risk and uncertainty can be identified and rectified.

The framework defines an evidential judgement as a case-based judgement about what one ought to believe about the world, given the available information. It therefore makes explicit the normative content inherent to judgements that may seem, on the face of it, to be predominantly technical. For example, priority-setter A acknowledges that the extrapolation of survival data can reasonably be modelled in different ways and that its evidential judgement about Gehrigole's cost per QALY is based in part on its view that the manufacturer's choice of model may have been influenced by its commercial interests. While HTA reports commonly include detailed (and often highly technical) information about such matters as model choice and estimated cost per QALY, acknowledgement of the normative considerations that underpin these types of judgement is typically lacking.

Case-based judgements that appear predominantly normative can also contain important empirical content. Priority-setter A states in its conclusion that Gehrigole's recommendation is justified in part by its 'innovative nature', implying that it considers innovative pharmacology to be inherently valuable.<sup>17</sup> However, the more detailed narrative situates the value of Gehrigole's innovativeness in its potential contribution to an eventual cure. The question of how large the future health benefits of such a cure might be, and how likely they are to be realised, are extremely difficult to resolve, but are nevertheless empirical rather than normative in nature. Still, priority-setter A's decision to contravene its own formal standard by taking account of these indirect benefits is shown through this narrative to be a normative one, based not on a notion of

<sup>17</sup>Innovative pharmacology is of course only one of several reasons why a drug might be considered innovative (Aronson *et al.*, 2012).

the inherent value of innovation but on the ‘significant unmet clinical need associated with ALS’.<sup>18</sup>

Perhaps most importantly, the framework makes explicit that evidential judgements cannot, by themselves, determine policy. That is, case-based judgements about *what should be believed* based on the available evidence (evidential judgements) cannot dictate *how one ought to act* as a result (ethical judgements). The truth of this statement can be easily overlooked where priority-setting is based on a single distributive principle, operationalised via a formal standard: for example, through strict application of a cost-effectiveness threshold. However, even under more nuanced approaches, the framework fulfils an important role in calling attention to normative judgements that might otherwise be misread (even by those making them) as technical.

#### 5.4 By helping to identify and resolve moral incoherence

In ethics, coherence is understood to be the alignment of considered moral judgements about particular cases with the principles, rules, or theoretical considerations that are believed to ground them (Daniels, 2016). One way of achieving such alignment is via reflective equilibrium, a dynamic process in which abstract and particular normative commitments that do not align with one another are re-examined, deliberated, and mutually adjusted until any inconsistencies or contradictions are resolved (Rawls, 1999; Arras, 2007). Under current norms, the conceptual and terminological issues already discussed can make it difficult for HTA bodies (and their stakeholders) to identify the commitments that have contributed both to a general approach to decision-making and to the judgements reached in specific cases. The framework can be used to make such commitments explicit, allowing the values, principles, standards, and case-based judgements adopted during assessment to be examined for alignment and facilitating reflective equilibrium.

In some cases, sources of incoherence may be easily identified, even without the additional clarity provided by the framework. For example, an HTA body that claims that its sole normative concern is efficiency, but which repeatedly recommends technologies that offer very poor value for money, is obviously in a state of incoherence. However, the framework improves accountability by making sources of incoherence explicit, requiring them to be either acknowledged or resolved. Priority-setter A echoes the behaviour of several real-world HTA bodies by assigning additional weight to the health needs of patients suffering from severe diseases. However, it fails to assign equivalent weight to other severely ill patients who suffer a proportion of the opportunity cost; a logical flaw that typically goes unacknowledged by HTA bodies but which priority-setter A is required to acknowledge through application of the framework.<sup>19</sup> The framework can also be used to highlight less obvious instances of incoherence. Take, for example, priority-setter A’s treatment of rarity. Priority-setter A claims that its substantive approach is underpinned by its principles of efficiency and equality. These principles are reflected as standards in priority-setter A’s use of a formal cost-effectiveness threshold, which ensures both that technologies are not recommended if they are likely to be inefficient and that all technologies are held to the same standard of efficiency. However, an informal standard has emerged from previous cases which allows this threshold to be exceeded if the estimated impact on resources is small. Priority-setter A acknowledges that patient population size (and, by extension, resource impact) does not appear to be a morally relevant consideration.<sup>20</sup> This informal standard

<sup>18</sup>One could imagine another priority-setter that held scientific progress to be one of its values and that would therefore have no need to translate the potential benefits of Gehrigole’s innovativeness into an estimate of future health benefits; rather, it would treat innovation as itself inherently valuable. Alternatively, a priority-setter might adopt a principle of actively supporting innovation in the pharmaceutical industry because of a commitment to the value of economic growth. Whether or not such normative commitments could be justified on either moral or social grounds remains to be seen.

<sup>19</sup>This is currently the subject of ongoing debate in the literature; see Paulden *et al.* (2014); Paulden and McCabe (2021); Charlton *et al.* (2022).

<sup>20</sup>The moral relevance of rarity remains contested, with a recent systematic review of reasons identifying a wide range of arguments both for and against prioritisation of drugs for rare diseases (Zimmerman *et al.*, 2021). However, strong arguments

therefore appears to contravene its principle of equality because it requires that cases that are alike in morally relevant respects (i.e. rare and common diseases) be treated differently. However, given that rare diseases have previously been prioritised under application of this standard, failure to apply it in the case of Gehrige would also require similar cases to be treated differently. These principles and standards are incoherent.

Having identified this problem, priority-setter A has several options. It can reject the informal standard that requires it to prioritise technologies for rare diseases and maintain that rarity is not a morally relevant consideration. Alternatively, it can accept the standard of prioritising rare diseases, working to understand the values and principles that have led to its establishment. In pursuing this option, priority-setter A might find it necessary to revise its values and principles or to reconsider how these are weighed against one another. If, for example, it finds that it has previously prioritised drugs indicated for rare diseases on the grounds that manufacturers deserve to be fairly rewarded for their investment in research, then this might lead to the acknowledgement of a further principle: a principle of reasonable commercial returns. Or if it discovers that its prioritisation of rare diseases in the past has derived from a belief that severely ill people have a right to potentially curative treatment, even when the costs are extremely high, then consideration should be given to how this might be formally incorporated into priority-setter A's approach and what changes may need to be made to accommodate it coherently. A third option, of course, would be for priority-setter A simply to accept that its decisions and approach are incoherent and thus cannot be morally justified. However, to do so would substantially weaken both its normative and perceived legitimacy and would make it vulnerable to entitled challenge from those who suffer disadvantage as a result of its recommendations. Such a response would also, by its nature, be unethical.

## 6. Conclusion

Decisions about which health care interventions to provide, and to whom, have substantial implications for the health and wellbeing of society and are fundamentally grounded in normative considerations about which reasonable people will disagree. These decisions must, therefore, be transparently reported and morally justified if they are to be seen as legitimate. At present, limitations in the language used to articulate normative reasoning are likely to undermine both perceived legitimacy and fairness.

The proposed framework provides a tool for more clearly articulating the rationale on which priority-setting decisions are based and allows decision-makers to be more explicit about how the available evidence has been evaluated, and the role that it has played in guiding them towards their conclusions. As such, it constitutes an attempt to strengthen the legitimacy of HTA as a tool for healthcare priority-setting and is offered for further debate and development by those in the academic and policy communities.

While we are mindful of the fact that language is socially and culturally situated and that the complete standardisation of long-established terms is neither feasible nor necessarily desirable, we believe that the concepts and definitions contained here can act as a useful reference point for those wishing to anchor their own terminology, contributing to greater clarity across disciplinary boundaries. The framework is also intended to assist those who seek to evaluate decision-making in order to hold healthcare priority-setters to account.<sup>21</sup> Most importantly, we hope that the tool set out here will facilitate practical public reasoning by providing HTA practitioners and policymakers with the

---

exist to support the position taken by priority-setter A and its conclusion that rarity is not in itself morally relevant is a reasonable one (Albertsen, 2022; Magalhaes, 2022).

<sup>21</sup>Ongoing work by members of our group is already demonstrating its utility as a research tool for those attempting to understand and morally evaluate the basis for healthcare priority-setting. VC and MD have recently used the framework as the basis for a coding frame for the analysis of key NICE policy documents, in order to identify the normative commitments embedded within the organisation's formal approach to priority-setting (publication forthcoming). VC is also currently using the framework as a tool to code the case-based judgements made by NICE in a collection of recent appraisals.

means to conceptualise, articulate, and evaluate the normative basis of their decision-making better and more easily, to the benefit of all those whose health these decisions impact.

**Financial support.** VC is funded by a Wellcome Trust Society and Ethics Doctoral Studentship (grant number 203351/Z/16/Z). AR's work is supported in part by the Clinical Center Department of Bioethics, which is in the Intramural Program of the US National Institutes of Health. LR's work is funded by Arnold Ventures. The views expressed here are those of the authors and do not necessarily reflect the views or policies of the organisations by which they are employed and/or funded.

**Competing interests.** AR is an employee of the Clinical Center Department of Bioethics, which is in the Intramural Program of the US National Institutes of Health. LR's research is supported by Arnold Ventures, a philanthropic organisation which invests in evidence-based solutions that maximise opportunity and minimise injustice. ZP-W is an employee of Leukaemia Care, a charitable body which receives funding from a wide range of sources, including the pharmaceutical industry. Details are available via the organisation's website and annual report. MS is an employee of the University of York, which receives funding to undertake technology assessment for the UK National Institute for Health and Care Excellence (NICE), which undertakes technology appraisal on behalf of the National Health Service in England and whose decision-making processes might be impacted by the issues raised in this manuscript. KS is an employee of NICE. All other authors have no competing interests.

**Ethical standard.** As this research was theoretical in nature, institutional ethics approval was not required.

## References

- Albertsen A** (2022) Rare diseases in healthcare priority setting: should rarity matter? *Journal of Medical Ethics* **48**, 624–628. doi: 10.1136/medethics-2020-106978
- Angelis A, Lange A and Kanavos P** (2018) Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries. *The European Journal of Health Economics* **19**, 123–152.
- Aronson J, Ferner R and Hughes D** (2012) Defining rewardable innovation in drug therapy. *Nature Reviews. Drug Discovery* **11**, 253–254.
- Arras J** (2007) The way we reason now: reflective equilibrium in bioethics. In Steinbock B (ed.), *The Oxford Handbook of Bioethics*. New York: Oxford University Press, pp. 46–71.
- Attema AE, Brouwer WBF and Claxton K** (2018) Discounting in economic evaluations. *Pharmacoeconomics* **36**, 745–758.
- Augustyn A** (2020) Lou Gehrig. *Britannica Online*. 11 March 2020. Available at <https://www.britannica.com/biography/Lou-Gehrig> (accessed 30 November 2021).
- Baker R, Mason H, McHugh N and Donaldson C** (2021) Public values and plurality in health priority setting: what to do when people disagree and why we should care about reasons as well as choices. *Social Science & Medicine* **277**, 113892. doi: 10.1016/j.socscimed.2021.113892
- Bellemare C, Dagenais P, K-Bedard S, Beland J, Bernier L, Charles-Etienne D, Gagnon H, Legault G, Parent M and Patenaude J** (2018) Ethics in health technology assessment: a systematic review. *International Journal of Technology Assessment in Health Care* **34**, 447–457.
- Biron L, Rumbold B and Faden R** (2012) Social value judgments in healthcare: a philosophical critique. *Journal of Health Organization and Management* **26**, 317–330.
- Buchanan A** (2002) Political legitimacy and democracy. *Ethics* **112**, 689–719.
- Bullement A, Taylor M, McMordie ST, Waters E and Hatswell AJ** (2019) NICE, in confidence: an assessment of redaction to obscure confidential information in single technology appraisals by the national institute for health and care excellence. *Pharmacoeconomics* **37**, 1383–1390. PMID: 31250397.
- Calnan M, Hashem F and Brown P** (2017) Still elegantly muddling through? NICE and uncertainty in decision making about the rationing of expensive medicines in England. *International Journal of Health Services* **47**, 571–594.
- Canadian Agency for Drugs and Technologies in Health** (2019) CADTH Canadian Drug Expert Committee Recommendation (Final): Nusinersen, 27 February 2019. Available at <https://cadth.ca/sites/default/files/cdr/complete/SR0576-Spinraza-Resubmission-Mar-1-19.pdf> (accessed 1 December 2021).
- Canadian Agency for Drugs and Technologies in Health** (2023) Procedures for CADTH Reimbursement Reviews, Version 15, February 2023. Available at [https://www.cadth.ca/sites/default/files/Drug\\_Review\\_Process/CADTH\\_Drug\\_Reimbursement\\_Review\\_Procedures.pdf](https://www.cadth.ca/sites/default/files/Drug_Review_Process/CADTH_Drug_Reimbursement_Review_Procedures.pdf) (accessed 20 February 2023).
- Charlton V** (2020) NICE and fair? Health technology assessment policy under the UK's national institute for health and care excellence, 1999–2018. *Health Care Analysis* **28**, 193–227.
- Charlton V** (2021) Justice, transparency and the guiding principles of the UK's National Institute for Health and Care Excellence. *Health Care Analysis* **30**, 115–145. doi: 10.1007/s10728-021-00444-y



- Charlton V and Weale A** (2021) Exorcising the positivist ghost in the priority-setting machine: NICE and the demise of the 'social value judgement'. *Health Economics, Policy, and Law* **16**, 505–511.
- Charlton V, Lomas J and Mitchell P** (2022) NICE's new methods: putting innovation first, but at what cost?. *BMJ* **379**, e071974. doi: 10.1136/bmj-2022-071974
- Clark S and Weale A** (2012) Social values in health priority setting: a conceptual framework. *Journal of Health Organization and Management* **26**, 293–316.
- Culyer A** (2016) Cost-effectiveness thresholds in health care: a bookshelf guide to their meaning and use. *Health Economics, Policy, and Law* **11**, 415–432.
- Culyer A and Husereau D** (2022) Redefining health technology assessment: a comment on 'The new definition of health technology assessment: a milestone in international collaboration'. *International Journal of Technology Assessment in Health Care*, **38**, e54.
- Culyer A and Lomas J** (2006) Deliberative processes and evidence-informed decision-making in health care: do they work and how might we know? *Evidence & Policy* **2**, 357–371.
- Daniels N** (2016) Reflective Equilibrium, 14 October 2016, in Zalta EN (ed.) The Stanford Encyclopedia of Philosophy. Summer 2020 Edition. Available at <https://plato.stanford.edu/archives/sum2020/entries/reflective-equilibrium/> (accessed 29 September 2021).
- Daniels N and Sabin J** (1997) Limits to health care: fair procedures, democratic deliberation, and the legitimacy problem for insurers. *Philosophy & Public Affairs* **26**, 303–350.
- Daniels N and Van der Wilt GJ** (2016) Health technology assessment, deliberative process, and ethically contested issues. *International Journal of Technology Assessment in Health Care* **32**, 10–15.
- Dawson A** (2009) Theory and practice in public health ethics: a complex relationship. In Peckham S and Hann A (eds), *Public Health Ethics and Practice*. Bristol: Policy Press, pp. 191–210.
- Dolan P** (1997) Modelling valuations for EuroQol health states. *Medical Care* **35**, 1095–1108.
- EUnetHTA** (2016) HTA Core Model Version 3.0. Available at <https://www.eunetha.eu/wp-content/uploads/2018/03/HTACoreModel3.0-1.pdf?x50316> (accessed 25 October 2021).
- Golan O, Hansen P, Kaplan G and Tal O** (2011) Health technology prioritization: which criteria for prioritizing new technologies and what are their relative weights? *Health Policy* **102**, 126–135.
- Goodman C** (1998) Health technology assessment: methods, framework, and role in policy making. *The American Journal of Managed Care* **4**, SP200–14.
- Haute Autorité de Santé** (2014) Methodological guide: assessment of ethical aspects. Available at [https://www.has-sante.fr/upload/docs/application/pdf/2014-11/assessment\\_of\\_ethical\\_aspects.pdf](https://www.has-sante.fr/upload/docs/application/pdf/2014-11/assessment_of_ethical_aspects.pdf) (accessed 29 September 2021).
- Haute Autorité de Santé** (2020) Transparency committee summary: Spinraza. 22 July 2020. Available at [https://www.has-sante.fr/upload/docs/application/pdf/2021-01/spinraza\\_22072020\\_summary\\_ct18244.pdf](https://www.has-sante.fr/upload/docs/application/pdf/2021-01/spinraza_22072020_summary_ct18244.pdf) (accessed 1 December 2021).
- Hofmann B** (2008) Why ethics should be part of health technology assessment. *International Journal of Technology Assessment in Health Care* **24**, 423–429.
- Hofmann B, Cleemput I, Bond K, Krones T, Droste S, Sacchini D and Oortwijn W** (2014) Revealing and acknowledging value judgements in health technology assessment. *International Journal of Technology Assessment in Health Care* **30**, 579–586.
- Hofmann B, Bond K and Sandman L** (2018) Evaluating facts and facting evaluations: on the fact–value relationship in HTA. *Journal of Evaluation in Clinical Practice* **24**, 957–965.
- HTAGlossary.net** (2021) Available at <http://htaglossary.net/HomePage> (accessed 29 September 2021).
- Hunter DJ** (1995) Rationing: the case for 'muddling through elegantly'. *BMJ* **311**, 811.
- Institute for Clinical and Economic Review** (2020) 2020–2023 Value Assessment Framework, 31 January 2020. Available at [https://icer.org/wp-content/uploads/2020/10/ICER\\_2020\\_2023\\_VAF\\_102220.pdf](https://icer.org/wp-content/uploads/2020/10/ICER_2020_2023_VAF_102220.pdf) (accessed 29 September 2021).
- Kaur G, Prinia S, Lakshmi P, Downey L, Sharma D and Teerawattananon Y** (2019) Criteria used for priority-setting for public health resource allocation in low- and middle-income countries: a systematic review. *International Journal of Technology Assessment in Health Care* **35**, 474–483.
- Legault GA, Gagnon H, Parent M, Bellemare C, Beland J, Kocsis-Bedard S, Bernier L, Dagenais P, Charles-Etienne D and Patenaude J** (2021) Integration of ethical considerations into HTA reports: an analysis of integration levels using a systematic review. *International Journal of Technology Assessment in Health Care* **37**, E61.
- Magalhaes M** (2022) Should rare diseases get special treatment? *Journal of Medical Ethics* **48**, 86–92.
- McCabe C, Claxton K and Culyer A** (2008) The NICE cost-effectiveness threshold: what it is and what that means. *Pharmacoeconomics* **26**, 733–744.
- Mechanic D** (1997) Muddling through elegantly: finding the proper balance in rationing. *Health Affairs* **16**, 83–92.
- National Institute for Clinical Excellence** (2005) *Social Value Judgements: Principles for the Development of NICE Guidance*, 1st Edn. London: NICE.
- National Institute for Health and Care Excellence** (2019) Nusinersen for treating spinal muscular atrophy, TA588, 24 July 2019. Available at <https://www.nice.org.uk/guidance/ta588/chapter/3-Committee-discussion#conclusion> (accessed 1 December 2021).



- National Institute for Health and Care Excellence** (2020) The principles that guide the development of NICE guidance and standards. Available at <https://www.nice.org.uk/about/who-we-are/our-principles> (accessed 29 September 2021).
- National Institute for Health and Clinical Excellence** (2008) *Social Value Judgements: Principles for the Development of NICE Guidance*, 2nd Edn. London: NICE.
- NICE** (2021). NICE strategy 2021 to 2026. Available at [www.nice.org.uk/strategy](http://www.nice.org.uk/strategy)
- Nicod E and Kanavos P** (2016) Scientific and social value judgments for orphan drugs in health technology assessment. *International Journal of Technology Assessment in Health Care* **32**, 218–232.
- O'Mahony J and Pauden M** (2014) NICE's selective application of differential discounting: ambiguous, inconsistent, and unjustified. *Value in Health* **17**, 493–496.
- Oortwijn W and Sampietro-Colom L** (2022) The Validate handbook: an approach on the integration of values in doing assessments of health technologies, Chapter 5: Ethics, ethics approaches in HTA, and ethics synthesis. Version 2.0. doi: 10.54195/CKHB1659
- Oortwijn W, Huserau D, Abelson J, Barasa E, Bayani D, Canuto Santos V, Culyer A, Facey K, Grainger D, Kieslich K, Ollendorf D, Pichon-Riviere A, Sandman L, Strammiello V and Teerawattananon Y** (2022) Designing and implementing deliberative processes for health technology assessment: a good practices report of a Joint HTAi/ISPOR task force. *International Journal of Technology Assessment in Health Care* **38**, e37.
- O'Rourke B, Oortwijn W, Schuller T and International Joint Task Group** (2020) The new definition of health technology assessment: a milestone in international collaboration. *International Journal of Technology Assessment in Health Care*, **36**, 187–190. doi: 10.1017/S02664623200000215
- Orr S, Wolff J and Morris S** (2011) What values should count in HTA for new medicines under value based pricing in the UK?. 31 August 2011. Available at <http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.404.5385&rep=rep1&type=pdf> (accessed 25 October 2021).
- Otto I, Kahrass H and Mertz M** (2021) 'Same same but different'? On the questionable but crucial differentiation between ethical and social aspects in health technology assessment. *Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen* **164**, 1–10.
- Paulden M and McCabe C** (2021) Modifying NICE's approach to equity weighting. *PharmacoEconomics* **39**, 147–160.
- Paulden M, O'Mahony J, Culyer A and McCabe C** (2014) Some inconsistencies in NICE's consideration of social values. *PharmacoEconomics* **32**, 1043–1053.
- Paulden M, O'Mahony J and McCabe C** (2017) Determinants of change in the cost-effectiveness threshold. *Medical Decision Making* **37**, 264–276.
- Pharmaceutical Benefits Advisory Committee** (2016) About the Guidelines. Available at <https://pbac.pbs.gov.au/information/about-the-guidelines.html> (accessed 29 September 2021).
- Pharmaceutical Benefits Advisory Committee** (2020) Public summary document, July 2020 PBAC Meeting: Nusinersen. Available at <https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2020-07/files/nusinersen-psd-july-2020.pdf> (accessed 1 December 2021).
- Rawlins M and Culyer A** (2004) National institute for clinical excellence and its value judgments. *BMJ* **329**, 224–227.
- Rawlins M, Barnett D and Stevens A** (2010) Pharmacoeconomics: NICE's approach to decision-making. *British Journal of Clinical Pharmacology* **70**, 346–349.
- Rawls J** (1999) *A Theory of Justice*, 2nd Edn. Cambridge, MA: Harvard University Press.
- Rumbold B, Weale A, Rid A, Wilson J and Littlejohns P** (2017) Public reasoning and health-care priority setting: the case of NICE. *Kennedy Institute of Ethics Journal* **27**, 107–134.
- Saarni S, Hofmann B, Lampe K, Lühmann D, Mäkelä M, Velasco-Garrido M and Autti-Rämö I** (2008) Ethical analysis to improve decision-making on health technologies. *Bulletin of the World Health Organization* **2008**, 617–623.
- Schokkaert E** (2015) How to introduce more (or better) ethical arguments in HTA?. *International Journal of Technology Assessment in Health Care* **31**, 1–2.
- Stafinski T, Menon D, Marshall D and Caulfield T** (2011) Societal values in the allocation of healthcare resources is it all about the health gain? *The Patient* **4**, 207–225.
- Steyaert C and Bouwen R** (2004) Group methods of organizational analysis. In Cassell C and Symon G (eds), *Essential Guide to Qualitative Methods in Organizational Research*. London: Sage Publications, pp. 140–153.
- Swedish Agency for Health Technology Assessment and Assessment of Social Services** (2018) Assessment of methods in health care and social services: a handbook, Preliminary version. Available at [https://www.sbu.se/contentassets/76adf07e270c48efaf67e3b560b7c59c/eng\\_metodboken.pdf](https://www.sbu.se/contentassets/76adf07e270c48efaf67e3b560b7c59c/eng_metodboken.pdf) (accessed 29 September 2021).
- Thokala P, Ochalek J, Leech A and Tong T** (2018) Cost-effectiveness thresholds: the past, the present and the future. *Pharmacoeconomics* **36**, 509–522.
- Trowman R, Powers A and Ollendorf DA** (2021) Considering and communicating uncertainty in health technology assessment. *International Journal of Technology Assessment in Health Care* **37**, e74.
- Weale A** (2010) Political theory and practical public reasoning. *Political Studies* **58**, 266–281.
- World Health Organisation** (2021) Health technology assessment. Available at <https://www.euro.who.int/en/health-topics/Health-systems/health-technologies-and-medicines/policy-areas/health-technology-assessment> (accessed 29 September 2021).

- York Health Economics Consortium** (2016) Glossary: reference case. Available at <https://yhec.co.uk/glossary/reference-case/> (accessed 29 September 2021).
- Zimmerman B, Eichinger J and Baumgartner M** (2021) A systematic review of moral reasons on orphan drug reimbursement. *Orphanet Journal of Rare Diseases* **16**, 292.